Following the approval by the Food and Drug Administration of Dsuvia (sufentanil) sublingual tablets for the management of acute pain severe enough to require an opioid analgesic in adult patients treated in a certified medically supervised healthcare setting, Clinical Pain Advisor sought feedback from its advisory board member, David Rosenblum, MD, director of pain medicine at Maimonides Medical Center in New York.
“I am very concerned about the recent approval of Dsuvia. While sulfentanil is a potent and effective pain killer, its abuse potential, if diverted, is worriesome. One can’t help but wonder why we need another ultra-fast acting opiate on the market. I have yet to see the studies, but will follow closely,” said Dr Rosenblum.
Tell us your thoughts on this issue, and find our where your colleagues stand: